Blog

The latest thoughts from Medicines Law & Policy partners.

The elephant in the room at the WHO Executive Board

The World Health Organization (WHO) Director-General, Dr Tedros Adhanom Ghebreyesus spoke harshly about the lack of Covid-19 vaccines in developing countries at the opening of...

Corbyn’s Compulsory Licenses. Will they work?

On 24 September, Jeremy Corbyn, leader of the UK Labour party, announced a series of measures to bring medicines pricing in check and to...

EU Review of Pharmaceutical Incentives: Recommendations for Change

In 2016, the European Council decided it was time for a review of the incentives that the EU provides to companies that develop new...

The People vs. AbbVie

Today, 9 May 2025, is an important day in court for the Dutch Pharmaceutical Accountability Foundation (PAF). In February 2023, PAF started a court...

The Urgency of Compulsory Licensing Provision for Transfer of Technology in the Pandemic Treaty:...

Guest blog by Ronald Eberhard The Intergovernmental Negotiating Body, established by the World Health Assembly, aims to draft a global pandemic prevention, preparedness, and response...

The European Commission’s proposal on a new EU-wide compulsory licensing regime

Guest author Olga Gurgula is a Senior Lecturer in Intellectual Property Law at Brunel Law School, Brunel University London A recent international health emergency, the...

Vaccine knowledge needs to be a global public good: Remarks to the World Trade...

Ellen ‘t Hoen, Medicines Law & Policy, at the World Trade Organization-World Health Organization High-Level Dialogue on Expanding COVID-19 Vaccine Manufacturing to Promote Equitable...

Dutch Health Care Institute Says No to Medicines Pirate

It seems the Dutch health care system and health care professionals are fed up with the abuse of the orphan medicines regulation, which is...

Brazil’s Federal Court Reviews Medicines Mailbox Patents

This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion...

High medicines prices in Europe – do not Brexit the people

The issues of high priced medicines and problems with access to medicines have for many years been themes belonging to the realm of global...